{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T06:54:24Z","timestamp":1775372064716,"version":"3.50.1"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI076119"],"award-info":[{"award-number":["AI076119"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI099284"],"award-info":[{"award-number":["AI099284"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI100890"],"award-info":[{"award-number":["AI100890"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI112417"],"award-info":[{"award-number":["AI112417"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["GM103368"],"award-info":[{"award-number":["GM103368"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.coviro.2014.06.002","type":"journal-article","created":{"date-parts":[[2014,7,2]],"date-time":"2014-07-02T17:15:26Z","timestamp":1404321326000},"page":"45-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"special_numbering":"C","title":["Antiviral drugs specific for coronaviruses in preclinical development"],"prefix":"10.1016","volume":"8","author":[{"given":"Adeyemi O","family":"Adedeji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan G","family":"Sarafianos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2014.06.002_bib0005","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","article-title":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia","volume":"367","author":"Zaki","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2014.06.002_sbref0010","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1126\/science.1085952","article-title":"Characterization of a novel coronavirus associated with severe acute respiratory syndrome","volume":"300","author":"Rota","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.coviro.2014.06.002_bib0015","doi-asserted-by":"crossref","first-page":"6676","DOI":"10.1128\/JVI.75.14.6676-6681.2001","article-title":"Viral replicase gene products suffice for coronavirus discontinuous transcription","volume":"75","author":"Thiel","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2014.06.002_bib0020","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1099\/vir.0.19424-0","article-title":"Mechanisms and enzymes involved in SARS coronavirus genome expression","volume":"84","author":"Thiel","year":"2003","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2014.06.002_bib0025","doi-asserted-by":"crossref","first-page":"8127","DOI":"10.1128\/JVI.74.17.8127-8134.2000","article-title":"Characterization of the coronavirus M protein and nucleocapsid interaction in infected cells","volume":"74","author":"Narayanan","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2014.06.002_bib0030","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1083\/jcb.131.2.339","article-title":"Envelope glycoprotein interactions in coronavirus assembly","volume":"131","author":"Opstelten","year":"1995","journal-title":"J Cell Biol"},{"key":"10.1016\/j.coviro.2014.06.002_bib0035","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1128\/JVI.01926-07","article-title":"Evidence of the recombinant origin of a bat severe acute respiratory syndrome (SARS)-like coronavirus and its implications on the direct ancestor of SARS coronavirus","volume":"82","author":"Hon","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2014.06.002_bib0040","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1126\/science.1118391","article-title":"Bats are natural reservoirs of SARS-like coronaviruses","volume":"310","author":"Li","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.coviro.2014.06.002_bib0045","first-page":"325","article-title":"Bats, civets and the emergence of SARS","volume":"315","author":"Wang","year":"2007","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.coviro.2014.06.002_bib0050","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S1473-3099(13)70690-X","article-title":"Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation","volume":"14","author":"Haagmans","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coviro.2014.06.002_bib0055","doi-asserted-by":"crossref","DOI":"10.1007\/s00705-014-1995-5","article-title":"Middle East respiratory syndrome coronavirus (MERS-CoV): evidence and speculations","author":"Abdel-Moneim","year":"2014","journal-title":"Arch Virol"},{"key":"10.1016\/j.coviro.2014.06.002_bib0060","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3201\/eid1903.121503","article-title":"Human betacoronavirus 2c EMC\/2012-related viruses in bats, Ghana and Europe","volume":"19","author":"Annan","year":"2013","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.coviro.2014.06.002_bib0065","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1099\/vir.0.049759-0","article-title":"Coronaviruses in bats from Mexico","volume":"94","author":"Anthony","year":"2013","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2014.06.002_bib0070","first-page":"3","article-title":"Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans","author":"van Boheemen","year":"2012","journal-title":"MBio"},{"key":"10.1016\/j.coviro.2014.06.002_bib0075","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.3201\/eid1910.130946","article-title":"Close relative of human Middle East respiratory syndrome coronavirus in bat, South Africa","volume":"19","author":"Ithete","year":"2013","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.coviro.2014.06.002_bib0080","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMra032498","article-title":"The severe acute respiratory syndrome","volume":"349","author":"Peiris","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2014.06.002_bib0085","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2217\/fvl.11.33","article-title":"Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy","volume":"6","author":"Barnard","year":"2011","journal-title":"Future Virol"},{"key":"10.1016\/j.coviro.2014.06.002_sbref0090","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2174\/156802606776287090","article-title":"Characterization and inhibition of SARS-coronavirus main protease","volume":"6","author":"Liang","year":"2006","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.coviro.2014.06.002_bib0095","doi-asserted-by":"crossref","first-page":"4718","DOI":"10.1128\/AAC.00957-12","article-title":"Severe acute respiratory syndrome coronavirus replication inhibitor that interferes with the nucleic acid unwinding of the viral helicase","volume":"56","author":"Adedeji","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2014.06.002_bib0100","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1126\/science.1085658","article-title":"Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs","volume":"300","author":"Anand","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.coviro.2014.06.002_sbref0105","doi-asserted-by":"crossref","first-page":"13190","DOI":"10.1073\/pnas.1835675100","article-title":"The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor","volume":"100","author":"Yang","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2014.06.002_bib0110","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1371\/journal.pbio.0030324","article-title":"Design of wide-spectrum inhibitors targeting coronavirus main proteases","volume":"3","author":"Yang","year":"2005","journal-title":"PLoS Biol"},{"key":"10.1016\/j.coviro.2014.06.002_bib0115","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1042\/BST0391371","article-title":"Recent development of 3C and 3CL protease inhibitors for anti-coronavirus and anti-picornavirus drug discovery","volume":"39","author":"Ramajayam","year":"2011","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.coviro.2014.06.002_bib0120","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.febslet.2008.12.059","article-title":"Individual and common inhibitors of coronavirus and picornavirus main proteases","volume":"583","author":"Kuo","year":"2009","journal-title":"FEBS Lett"},{"key":"10.1016\/j.coviro.2014.06.002_bib0125","doi-asserted-by":"crossref","first-page":"7849","DOI":"10.1016\/j.bmc.2010.09.050","article-title":"Synthesis and evaluation of pyrazolone compounds as SARS-coronavirus 3C-like protease inhibitors","volume":"18","author":"Ramajayam","year":"2010","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.coviro.2014.06.002_bib0130","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.febslet.2004.08.015","article-title":"Evaluation of metal-conjugated compounds as inhibitors of 3CL protease of SARS-CoV","volume":"574","author":"Hsu","year":"2004","journal-title":"FEBS Lett"},{"key":"10.1016\/j.coviro.2014.06.002_bib0135","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1016\/j.febslet.2007.10.048","article-title":"Structural basis of mercury- and zinc-conjugated complexes as SARS-CoV 3C-like protease inhibitors","volume":"581","author":"Lee","year":"2007","journal-title":"FEBS Lett"},{"key":"10.1016\/j.coviro.2014.06.002_bib0140","doi-asserted-by":"crossref","first-page":"10012","DOI":"10.1073\/pnas.0403596101","article-title":"Small molecules targeting severe acute respiratory syndrome human coronavirus","volume":"101","author":"Wu","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2014.06.002_bib0145","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/cbic.200700254","article-title":"Structure-based design and synthesis of highly potent SARS-CoV 3CL protease inhibitors","volume":"8","author":"Shao","year":"2007","journal-title":"Chembiochem"},{"key":"10.1016\/j.coviro.2014.06.002_bib0150","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.1016\/j.bmc.2005.05.065","article-title":"Inhibition of the severe acute respiratory syndrome 3CL protease by peptidomimetic alpha,beta-unsaturated esters","volume":"13","author":"Shie","year":"2005","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.coviro.2014.06.002_bib0155","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1021\/jm050184y","article-title":"Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease","volume":"48","author":"Shie","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.coviro.2014.06.002_bib0160","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.chembiol.2005.12.008","article-title":"Stable benzotriazole esters as mechanism-based inactivators of the severe acute respiratory syndrome 3CL protease","volume":"13","author":"Wu","year":"2006","journal-title":"Chem Biol"},{"key":"10.1016\/j.coviro.2014.06.002_bib0165","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1021\/jm050852f","article-title":"Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies","volume":"49","author":"Tsai","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.coviro.2014.06.002_bib0170","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1021\/jm051129s","article-title":"Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro\/in vivo biological activities","volume":"49","author":"Lu","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.coviro.2014.06.002_bib0175","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1016\/j.bmc.2008.02.040","article-title":"Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease","volume":"16","author":"Shao","year":"2008","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.coviro.2014.06.002_bib0180","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1016\/j.bmcl.2010.04.118","article-title":"Synthesis, docking studies, and evaluation of pyrimidines as inhibitors of SARS-CoV 3CL protease","volume":"20","author":"Ramajayam","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.coviro.2014.06.002_bib0185","doi-asserted-by":"crossref","first-page":"13600","DOI":"10.1128\/JVI.78.24.13600-13612.2004","article-title":"Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity","volume":"78","author":"Harcourt","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2014.06.002_bib0190","doi-asserted-by":"crossref","first-page":"15189","DOI":"10.1128\/JVI.79.24.15189-15198.2005","article-title":"The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity","volume":"79","author":"Barretto","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2014.06.002_bib0195","doi-asserted-by":"crossref","first-page":"e28479","DOI":"10.1371\/journal.pone.0028479","article-title":"Yeast based small molecule screen for inhibitors of SARS-CoV","volume":"6","author":"Frieman","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2014.06.002_bib0200","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0959-440X(05)80116-2","article-title":"Helicases: amino acid sequence comparisons and structure function relationships","volume":"3","author":"Gorbalenya","year":"1993","journal-title":"Curr Opin Struct Biol"},{"key":"10.1016\/j.coviro.2014.06.002_sbref0205","doi-asserted-by":"crossref","first-page":"e36521","DOI":"10.1371\/journal.pone.0036521","article-title":"Mechanism of nucleic acid unwinding by SARS-CoV helicase","volume":"7","author":"Adedeji","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2014.06.002_bib0210","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1099\/0022-1317-81-5-1335","article-title":"Enzymatic properties of hepatitis C virus NS3-associated helicase","volume":"81","author":"Paolini","year":"2000","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2014.06.002_bib0215","doi-asserted-by":"crossref","first-page":"5698","DOI":"10.1016\/j.ejmech.2011.09.005","article-title":"2,6-Bis-arylmethyloxy-5-hydroxychromones with antiviral activity against both hepatitis C virus (HCV) and SARS-associated coronavirus (SCV)","volume":"46","author":"Kim","year":"2011","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.coviro.2014.06.002_bib0220","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.bmcl.2009.02.010","article-title":"Aryl diketoacids (ADK) selectively inhibit duplex DNA-unwinding activity of SARS coronavirus NTPase\/helicase","volume":"19","author":"Lee","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.coviro.2014.06.002_bib0225","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.chembiol.2005.01.006","article-title":"The adamantane-derived bananins are potent inhibitors of the helicase activities and replication of SARS coronavirus","volume":"12","author":"Tanner","year":"2005","journal-title":"Chem Biol"},{"key":"10.1016\/j.coviro.2014.06.002_bib0230","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.4155\/fmc.13.183","article-title":"Future treatment strategies for novel Middle East respiratory syndrome coronavirus infection","volume":"5","author":"Adedeji","year":"2013","journal-title":"Future Med Chem"},{"issue":"8","key":"10.1016\/j.coviro.2014.06.002_bib0235","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02994-14","article-title":"Evaluation of SSYA10-001 as a replication inhibitor of SARS, MHV and MERS coronaviruses","volume":"58","author":"Adedeji","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2014.06.002_bib0240","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0065-3527(05)65005-1","article-title":"Alteration and analyses of viral entry with library-derived peptides","volume":"65","author":"Bupp","year":"2005","journal-title":"Adv Virus Res"},{"key":"10.1016\/j.coviro.2014.06.002_bib0245","doi-asserted-by":"crossref","first-page":"5054","DOI":"10.1128\/JVI.77.9.5054-5064.2003","article-title":"Inhibition of respiratory syncytial virus fusion by the small molecule VP-14637 via specific interactions with F protein","volume":"77","author":"Douglas","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2014.06.002_bib0250","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1074-5521(01)00042-4","article-title":"RFI-641 inhibits entry of respiratory syncytial virus via interactions with fusion protein","volume":"8","author":"Razinkov","year":"2001","journal-title":"Chem Biol"},{"key":"10.1016\/j.coviro.2014.06.002_bib0255","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0149-2918(08)80048-3","article-title":"Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection","volume":"30","author":"Lieberman-Blum","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.coviro.2014.06.002_bib0260","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1086\/589289","article-title":"Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents","volume":"47","author":"MacArthur","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coviro.2014.06.002_bib0265","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0079-6468(05)43007-6","article-title":"The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS","volume":"43","author":"Wood","year":"2005","journal-title":"Prog Med Chem"},{"key":"10.1016\/j.coviro.2014.06.002_bib0270","first-page":"347","article-title":"Pentafuside. DP 178, T 20","volume":"2","author":"Anonymous","year":"1999","journal-title":"Drugs R D"},{"key":"10.1016\/j.coviro.2014.06.002_bib0275","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.coviro.2012.01.002","article-title":"Is there a future for antiviral fusion inhibitors?","volume":"2","author":"Berkhout","year":"2012","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.coviro.2014.06.002_bib0280","doi-asserted-by":"crossref","first-page":"8358","DOI":"10.1128\/JVI.74.18.8358-8367.2000","article-title":"Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120","volume":"74","author":"Derdeyn","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2014.06.002_bib0285","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1006\/bbrc.2000.2846","article-title":"The HIV-1 cell entry inhibitor T-20 potently chemoattracts neutrophils by specifically activating the N-formylpeptide receptor","volume":"272","author":"Hartt","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.coviro.2014.06.002_bib0290","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.drup.2004.03.003","article-title":"HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications","volume":"7","author":"Miller","year":"2004","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.coviro.2014.06.002_bib0295","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1128\/AAC.01211-08","article-title":"SC29EK, a peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide","volume":"53","author":"Naito","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2014.06.002_bib0300","doi-asserted-by":"crossref","first-page":"5563","DOI":"10.1128\/JVI.02095-05","article-title":"Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affords sterile protection of monkeys against a heterologous simian\/human immunodeficiency virus infection","volume":"80","author":"Eda","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2014.06.002_bib0305","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3233\/HAB-2005-143-405","article-title":"Ex vivo neutralization of HIV-1 quasi-species by a broadly reactive humanized monoclonal antibody KD-247","volume":"14","author":"Matsushita","year":"2005","journal-title":"Hum Antibodies"},{"key":"10.1016\/j.coviro.2014.06.002_bib0310","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.virol.2005.05.027","article-title":"Use of alternate coreceptors on primary cells by two HIV-1 isolates","volume":"339","author":"Cilliers","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2014.06.002_bib0315","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2165\/00003495-200969010-00003","article-title":"Novel targets for antiretroviral therapy: clinical progress to date","volume":"69","author":"Dau","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.coviro.2014.06.002_bib0320","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nrmicro2147","article-title":"Coronaviruses post-SARS: update on replication and pathogenesis","volume":"7","author":"Perlman","year":"2009","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.coviro.2014.06.002_bib0325","doi-asserted-by":"crossref","first-page":"8801","DOI":"10.1128\/JVI.77.16.8801-8811.2003","article-title":"The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex","volume":"77","author":"Bosch","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2014.06.002_bib0330","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.bbrc.2004.05.114","article-title":"Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor","volume":"319","author":"Hofmann","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.coviro.2014.06.002_sbref0335","doi-asserted-by":"crossref","first-page":"11876","DOI":"10.1073\/pnas.0505577102","article-title":"Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry","volume":"102","author":"Simmons","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2014.06.002_bib0340","doi-asserted-by":"crossref","first-page":"20836","DOI":"10.1074\/jbc.M400759200","article-title":"Structural characterization of the SARS-coronavirus spike S fusion protein core","volume":"279","author":"Tripet","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2014.06.002_sbref0345","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1074\/jbc.C300520200","article-title":"A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2","volume":"279","author":"Wong","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2014.06.002_bib0350","doi-asserted-by":"crossref","first-page":"5642","DOI":"10.1128\/JVI.78.11.5642-5650.2004","article-title":"Nabel GJ: pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN","volume":"78","author":"Yang","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2014.06.002_bib0355","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/S0092-8674(03)00976-0","article-title":"The secret life of ACE2 as a receptor for the SARS virus","volume":"115","author":"Dimitrov","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.coviro.2014.06.002_bib0360","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.bbrc.2003.11.054","article-title":"The SARS-CoV S glycoprotein: expression and functional characterization","volume":"312","author":"Xiao","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.coviro.2014.06.002_bib0365","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1124\/mol.110.064261","article-title":"A small-molecule oxocarbazate inhibitor of human cathepsin L blocks severe acute respiratory syndrome and ebola pseudotype virus infection into human embryonic kidney 293T cells","volume":"78","author":"Shah","year":"2010","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.coviro.2014.06.002_bib0370","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.antiviral.2011.12.012","article-title":"A hexapeptide of the receptor-binding domain of SARS corona virus spike protein blocks viral entry into host cells via the human receptor ACE2","volume":"94","author":"Struck","year":"2012","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2014.06.002_bib0375","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.antiviral.2011.07.016","article-title":"Inhibitors of SARS-CoV entry\u2014identification using an internally-controlled dual envelope pseudovirion assay","volume":"92","author":"Zhou","year":"2011","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2014.06.002_sbref0380","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1073\/pnas.0306446101","article-title":"Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry","volume":"101","author":"Simmons","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2014.06.002_sbref0385","doi-asserted-by":"crossref","first-page":"8017","DOI":"10.1128\/JVI.00998-13","article-title":"Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms","volume":"87","author":"Adedeji","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2014.06.002_bib0390","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1161\/01.HYP.0000146120.29648.36","article-title":"Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor","volume":"44","author":"Huentelman","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.coviro.2014.06.002_sbref0395","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus","volume":"426","author":"Li","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2014.06.002_bib0400","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1161\/01.RES.0000205761.22353.5f","article-title":"Angiotensin-converting enzyme II in the heart and the kidney","volume":"98","author":"Danilczyk","year":"2006","journal-title":"Circ Res"},{"key":"10.1016\/j.coviro.2014.06.002_bib0405","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/S0140-6736(03)13412-5","article-title":"Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study","volume":"361","author":"Peiris","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2014.06.002_bib0410","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/thx.2003.014076","article-title":"Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak","volume":"59","author":"Sung","year":"2004","journal-title":"Thorax"},{"key":"10.1016\/j.coviro.2014.06.002_bib0415","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1001\/jama.289.21.JOC30885","article-title":"Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area","volume":"289","author":"Booth","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.coviro.2014.06.002_bib0420","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1001\/jama.290.24.3222","article-title":"Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study","volume":"290","author":"Loutfy","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.coviro.2014.06.002_bib0425","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax"},{"key":"10.1016\/j.coviro.2014.06.002_bib0430","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/srep01686","article-title":"Inhibition of novel beta coronavirus replication by a combination of interferon-alpha2b and ribavirin","volume":"3","author":"Falzarano","year":"2013","journal-title":"Sci Rep"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625714001370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625714001370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T06:32:14Z","timestamp":1565591534000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625714001370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":86,"alternative-id":["S1879625714001370"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2014.06.002","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiviral drugs specific for coronaviruses in preclinical development","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2014.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}